Phase II/III CRO Benchmarking—Small Pharma Market (2nd Ed.)

Description

Industry Standard Research understands the desire for a deeper dive regarding the small and emerging biopharma landscape. Are the needs, perceptions, and interactions of this segment different compared to the wider audience of Phase II/III clinical development outsourcers? In a word, yes. The goal, therefore, of this small and emerging biopharma report is two-fold. First, this research will help small and emerging biopharma companies make more informed CRO selection decisions. Second, these findings will help CROs optimize operational and marketing strategies to better accommodate small and emerging biopharma companies.

As these companies continue to increase their role in drug development and innovation, we at ISR know the importance of keeping a pulse on this subset. Our goal remains the same–provide quality market research to ensure both sponsors and providers can glean what they need to make the best decisions possible for their clinical development programs and service offerings.

Report cover for "PHASE II/III CRO Benchmarking—Small Pharma Market" June, 2021

Small & Emerging Sponsors:

  • Make smarter CRO outsourcing decisions by learning which service providers line up with your company’s needs
  • Discover the CRO attributes driving outsourcing choices for Phase II/III clinical research, as well as which attributes are increasing in importance over the last 12 months among industry peers
  • Find which CROs have the highest customer loyalty scores—as determined via customer satisfaction, willingness to recommend, and likelihood to use again ratings

Service Providers:

  • Refine your marketing efforts by focusing on what customers say makes your organization stand out to small & emerging biopharma companies
  • Uncover the factors influencing small & emerging sponsor outsourcing preferences, and which factors are increasing in importance for future outsourcing
  • Service Provider Selection Process
  • Service Provider Perceptions and Interactions
  • Study Data
  • Demographics

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.

"For Marketing Professionals | Service Provider Familiarity p. 38 | Service Provider Selection Attributes p. 15"

Service Provider Selection Process

Primary Section Takeaways
Preferred Provider Agreements
Number of Preferred Providers
Selection Drivers: No Preferred Providers
Service Provider Attributes Gaining Importance:
No Preferred Providers
Use of Outside Consultants
Respondent Comments

Service Provider Perceptions and Interactions

Primary Section Takeaways
Leadership, Familiarity, and Use
Service Provider Preference
Service Provider Preference among Users
Cost Perceptions
Cost Experience among Users
Summary Table
CRO Loyalty
Respondent Comments

Study Data

Phase II/III Leaders, Unprompted
Phase II/III Leaders, Prompted
Service Provider Familiarity
Service Provider Familiarity – Additional Providers
Service Provider Usage
Service Provider Preference
Service Provider Differentiation
Service Provider Cost Perceptions
Use of Preferred Providers
Number of Preferred Providers
Selection Drivers: Selecting among Preferred Providers
Preferred Provider Attributes Gaining Importance
Selection Drivers: When Not Using Preferred Providers
Selection Drivers: No Preferred Providers
Service Provider Attributes Gaining Importance:
No Preferred Providers
Use of Outside Consultants
Outside Consultant Assistance

Demographics

Company Type
Headquarters Location
Office Location
Job Title
Decision-making Responsibility
Outsourcing Involvement by Phase
Involvement in Clinical Development
Therapeutic Areas of Responsibility
Years of Industry Experience
Age
About Industry Standard Research

Additional information

License

, ,